ERAS Logo

Erasca, Inc. (ERAS) 

NASDAQ
Market Cap
$732.26M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
82 of 774
Rank in Industry
59 of 432

Largest Insider Buys in Sector

ERAS Stock Price History Chart

ERAS Stock Performance

About Erasca, Inc.

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients …

Insider Activity of Erasca, Inc.

Over the last 12 months, insiders at Erasca, Inc. have bought $1.95M and sold $0 worth of Erasca, Inc. stock.

On average, over the past 5 years, insiders at Erasca, Inc. have bought $9.04M and sold $3.75M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Lim Jonathan E (Chairman & CEO) — $3.39M. Casdin Alexander W. (director) — $231,705. Start Valerie Denise Harding (director) — $18,480.

The last purchase of 80,000 shares for transaction amount of $181,920 was made by Casdin Alexander W. (director) on 2024‑05‑21.

List of Insider Buy and Sell Transactions, Erasca, Inc.

2024-05-21Purchasedirector
80,000
0.0447%
$2.27$181,920+16.17%
2023-12-06PurchaseChairman & CEO
278,150
0.1825%
$1.72$478,418+25.28%
2023-12-06Purchasedirector
10,000
0.007%
$1.85$18,480+25.28%
2023-12-05PurchaseChairman & CEO
721,850
0.4606%
$1.69$1.22M+26.07%
2023-12-04Purchasedirector
30,000
0.0197%
$1.66$49,785+30.27%
2023-10-05PurchaseChairman & CEO
1M
0.695%
$2.03$2.03M+2.83%
2023-06-08PurchaseChairman & CEO
100,000
0.0676%
$2.75$275,000-18.38%
2023-04-10Purchasedirector
20,000
0.0135%
$2.76$55,230-14.44%
2023-03-28PurchaseChairman & CEO
100,000
0.0693%
$2.84$284,000-12.41%
2023-01-10PurchaseChairman & CEO
60,000
0.0413%
$3.86$231,420-29.33%
2022-12-21Purchasedirector
20,000
0.0162%
$4.14$82,800-35.48%
2022-12-21Purchasedirector
10,000
0.0091%
$4.64$46,400-35.48%
2022-12-15Purchasedirector
20,000
0.0167%
$4.87$97,490-42.71%
2022-12-14PurchaseChairman & CEO
40,000
0.0338%
$4.99$199,600-43.44%
2022-12-13Purchasedirector
307,692
0.3325%
$6.50$2M-44.42%
2021-08-10Purchasedirector
200,000
0.2202%
$22.10$4.42M-41.38%
2021-07-26Saledirector
200,000
0.2009%
$18.77$3.75M-35.23%
2021-07-20Purchasedirector
950,000
0.7974%
$16.00$15.2M-35.39%
2021-07-20Purchasedirector
6,200
0.0052%
$16.00$99,200-35.39%
2021-07-20Purchasedirector
6,000
0.005%
$16.00$96,000-35.39%

Insider Historical Profitability

<0.0001%
Lim Jonathan EChairman & CEO
12899360
4.5625%
$2.5970<0.0001%
Casdin Alexander W.director
573974
0.203%
$2.5940<0.0001%
Start Valerie Denise Hardingdirector
20000
0.0071%
$2.5930<0.0001%
Chen Bihuadirector
10813246
3.8246%
$2.5931<0.0001%
Multani Pratik Sdirector
172866
0.0611%
$2.5910<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Arch Venture Management Llc$22.77M4.6511.06M0%+$01.12
BlackRock$14.38M2.936.98M-4.5%-$678,051.10<0.0001
Armistice Capital Llc$12.71M2.596.17M-23.77%-$3.96M0.04
Artal Group S A$9.73M1.984.72M0%+$00.04
The Vanguard Group$8.94M1.824.34M+14.39%+$1.12M<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.